Zobrazeno 1 - 10
of 205
pro vyhledávání: '"Tetsuzo Tauchi"'
Publikováno v:
PLoS ONE, Vol 19, Iss 7, p e0307662 (2024)
Promising outcomes have been reported in elder patients with acute myeloid leukemia (AML) using combined therapy of venetoclax (VEN) and azacytidine (AZA) in recent years. However, approximately one-third of patients appear to be refractory to this t
Externí odkaz:
https://doaj.org/article/41c15908f9024d1583b15934784765e2
Autor:
Seiichiro Katagiri, Tetsuzo Tauchi, Keiko Ando, Seiichi Okabe, Moritaka Gotoh, Kazuma Ohyashiki
Publikováno v:
Leukemia Research Reports, Vol 7, Iss C, Pp 33-35 (2017)
It is difficult to predict musculoskeletal pain as a withdrawal syndrome following the discontinuation of imatinib (IM) in patients with chronic myeloid leukemia. We investigated a link between physical size and musculoskeletal pain following IM disc
Externí odkaz:
https://doaj.org/article/3f696ddf8c4e462bac7ed180abb10537
Autor:
Seiichi Okabe, Tetsuzo Tauchi, Shinya Kimura, Taira Maekawa, Toshihiko Kitahara, Yoko Tanaka, Kazuma Ohyashiki
Publikováno v:
PLoS ONE, Vol 9, Iss 2, p e89080 (2014)
Resistance to imatinib (Gleevec®) in cancer cells is frequently because of acquired point mutations in the kinase domain of BCR-ABL. Ponatinib, also known as AP24534, is an oral multi-targeted tyrosine kinase inhibitor (TKI), and it has been investi
Externí odkaz:
https://doaj.org/article/dcb8e3f5c84b48aaa5c143213c192005
Autor:
Kazuma Ohyashiki, Tomohiro Umezu, Seiichiro Katagiri, Chiaki Kobayashi, Kenko Azuma, Tetsuzo Tauchi, Seiichi Okabe, Yutaka Fukuoka, Junko H. Ohyashiki
Publikováno v:
International Journal of Molecular Sciences, Vol 17, Iss 4, p 570 (2016)
Approximately 40% of chronic myeloid leukemia (CML) patients who discontinue imatinib (IM) therapy maintain undetectable minimal residual disease (UMRD) for more than one year (stopping IM (STOP-IM)). To determine a possible biomarker for STOP-IM CML
Externí odkaz:
https://doaj.org/article/26b972650c644cddbd4724525d698bf0
Autor:
Kazuma Ohyashiki, Tomoki Naoe, Taira Maekawa, Shinya Kimura, Yosuke Minami, Seiichi Okabe, Tetsuzo Tauchi, Seiichiro Katagiri
Purpose: The Hedgehog signaling pathway is a key regulator of cell growth and differentiation during development. Whereas the Hedgehog pathway is inactive in most normal adult tissues, Hedgehog pathway reactivation has been implicated in the pathogen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::113b1c28a5034b79376a39f67162cb8d
https://doi.org/10.1158/1078-0432.c.6522191
https://doi.org/10.1158/1078-0432.c.6522191
Autor:
Kazuma Ohyashiki, Tomoki Naoe, Taira Maekawa, Shinya Kimura, Yosuke Minami, Seiichi Okabe, Tetsuzo Tauchi, Seiichiro Katagiri
PDF file - 47 KB, SK-9 cells were treated with 1 mM of nilotinib or 200 nM of dasatinib or 40 nM of ponatinib for 48 hrs. The cytoplasmic cell lysates and nuclear extracts were immunoblotted with anti-Gli1 Abs or anti-ABL Ab.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::396c07f9140371cc64322e1351e6a918
https://doi.org/10.1158/1078-0432.22451411
https://doi.org/10.1158/1078-0432.22451411
Autor:
Kazuma Ohyashiki, Tomoki Naoe, Taira Maekawa, Shinya Kimura, Yosuke Minami, Seiichi Okabe, Tetsuzo Tauchi, Seiichiro Katagiri
CCR Translation for This Article from Combination of Ponatinib with Hedgehog Antagonist Vismodegib for Therapy-Resistant BCR-ABL1–Positive Leukemia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1113f10e93c80824c297a74da41f5c89
https://doi.org/10.1158/1078-0432.22451414.v1
https://doi.org/10.1158/1078-0432.22451414.v1
Autor:
Geoffrey Chan, Hervé Dombret, Barbara Sleight, Xiaoxi Zhang, Mikkael A. Sekeres, Timothy J Bell, Eric Leip, Christine DiRienzo, Naveed Shaik, Akil Merchant, Tetsuzo Tauchi, Jorge E. Cortes
Publikováno v:
Future Oncology. 15:3531-3545
Glasdegib, an oral Hedgehog pathway inhibitor, has been associated with significantly improved survival when combined with low-dose cytarabine in patients with untreated acute myeloid leukemia (AML) who were unsuitable for intensive chemotherapy, whe
Autor:
Tomohiro Morio, Tsubasa Okano, Yujin Sekinaka, Eri Endo, Katsuyuki Hanabusa, Ikuya Tsuge, Shiann Tarng Jou, Masataka Ishimura, Hsin-Hui Yu, Yoshihiro Maruo, Tomiko Kimoto, Tomoaki Kunitsu, Hiroshi Yagasaki, Masami Inoue, Kenichi Yoshida, Yuki Tsujita, Taizo Wada, Kohsuke Imai, Kyoko Suzuki, Seiji Kojima, Sven Kracker, Tetsuzo Tauchi, Yuko Hashimoto, Takehiro Takashima, Yuzaburo Inoue, Toru Uchiyama, Hidetoshi Takada, Kenichi Honma, Motohiro Kato, Masakazu Nagahori, Takashi Kaneko, Yoshiaki Shikama, Naohiko Moriguchi, Tomoko Waragai, Daiei Kojima, Haruka Hiroki, Tamaki Kato, Kanako Mitsui-Sekinaka, Keisuke Tanaka, Anne Durandy, Yuki Bando, Hideki Muramatsu, Kazuhiro Tasaki, Seishi Ogawa, Hirokazu Kanegane, Fuminori Iwasaki, Shigeaki Nonoyama, Tzu Wen Yeh, Chikako Kamae, Toshihiko Shirakawa, Osamu Suzuki, Tomoyo Matsubara, Hideki Sano, Yuki Yuza, Osamu Ohara, Noriko Mitsuiki
Publikováno v:
Journal of Allergy and Clinical Immunology. 143:266-275
Background Activated phosphatidylinositol-3-OH kinase δ syndrome type 1 (APDS1) is a recently described primary immunodeficiency syndrome characterized by recurrent respiratory tract infections, lymphoid hyperplasia, and Herpesviridae infections cau
Publikováno v:
Annals of Hematology. 98:723-733
Multiple myeloma (MM) is a uniformly fatal disorder of B cells characterized by the accumulation of abnormal plasma cells. Phosphoinositide 3-kinase (PI3K) signaling pathways play a critical regulatory role in MM pathology. Copanlisib, also known as